Agilent Technologies Inc. (NYSE: A) has received a 2017 Scientists' Choice Award for Best New Clinical Laboratory Product: the IQFISH Panel for Lung Cancer. The IQFISH panel for lung cancer makes it easier for pathology labs to integrate fast, high-quality FISH (fluorescent in situ hybridization) into their IHC workflows.

The announcement was made during a special ceremony held during the AACC Annual Scientific Meeting & Clinical Lab Expo 2017 held early August in San Diego, USA. AACC highlights the most exciting clinical developments from institutions all over the world. As it does each year, scientists around the world were invited to participate in the Scientists' Choice Awards by nominating, voting and reviewing online.

"We are delighted and honored to receive this award, especially because the voters were scientists themselves," says Jeff Heimburger, head of genomics marketing for Agilent. "Not only is this a recognition of product quality and innovation, it also shows that we're listening to our customers and developing the right products that help them fight cancer."
Non-small-cell lung cancer can involve certain genetic aberrations. The IQFISH panel for lung cancer can help detect rearrangements involving those genes, yielding information that can help guide treatment options. With this technology, multiple FISH slides can be processed in just four hours, whereas traditional FISH can take two or more days.

The IQFISH panel launched in Europe in 2016 and is CE-IVD labeled. It is not available for sale in the U.S.

The annual Scientists' Choice Awards celebrate the laboratory products and manufacturers that make a difference to the industry. SelectScience began the Scientists' Choice Awards in 2007 to enable scientists to voice their opinions on the best laboratory products. Scientists are then invited to vote for their favorite products within each category, and the winners are announced at scientific conferences.